FdaApplication
NDA 210655
Identifiers
- fda_app_no: NDA210655
Properties
| Property | Value |
|---|---|
| applicant_name | INDIVIOR INC |
| application_type | NDA |
| approval_date | 2018-07-27 |
Revenue by product
PERSERIS KIT
| Period | Revenue |
|---|---|
| Q2 2026 | $5.0M |
| Q1 2026 | $5.0M |
| Q4 2025 | $5.0M |
| Q3 2025 | $6.0M |
| Q2 2025 | $8.0M |
| Q1 2025 | $4.0M |
| Q4 2024 | $9.0M |
| Q3 2024 | $8.0M |
| Q2 2024 | $13.0M |
| Q1 2024 | $11.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PERSERIS KIT | RISPERIDONE | 90MG | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS |
| PERSERIS KIT | RISPERIDONE | 120MG | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS |
2 products